H&N Cancer Market to Reach $2.6B by 2032
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
targeted therapy
Zenocutuzumab Extends Benefit in NRG1+ NSCLC
LEXINGTON, Mass., February 20, 2026 — New findings from a post hoc analysis of the ongoing eNRGy trial reveal...
Retevmo Shows Strong Survival Benefit in RET+ Lung Cancer
INDIANAPOLIS, Feb. 16, 2026 — Eli Lilly and Company announced positive Phase III results demonstrating that Retevmo® (selpercatinib) delivered...
Oncology NGS Market Accelerates as Precision Medicine Grows
Boston, MA – December 2025 – The global Clinical Oncology Next-Generation Sequencing (NGS) market is expanding rapidly as cancer...
Five-Year REZLIDHIA Data Reinforces Long-Term AML Outcomes
Dateline IntroductionNovember 18, 2025 — South San Francisco, CA — Rigel Pharmaceuticals has published final five-year clinical data on...
BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
Crinetics Unveils Neuroendocrine Tumour Data at NANETS 2025
SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...
Pfizer’s TUKYSA Shows Strong Benefit in First-Line HER2+ Breast Cancer
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...